About ReAlta Life Sciences
ReAlta Life Sciences is a company based in Norfolk (United States) founded in 2018. It operates as a HealthTech. ReAlta Life Sciences has raised $121.5 million across 5 funding rounds from investors including Marathon Pharma. The company has 19 employees as of December 31, 2021. ReAlta Life Sciences offers products and services including RLS-0071 (pegtarazimod) and EPICC Platform. ReAlta Life Sciences operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Norfolk, United States
- Employees 19 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Realta Life Sciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$121.5 M (USD)
in 5 rounds
-
Latest Funding Round
$40 M (USD), Series C
Apr 08, 2026
- Investors
-
Employee Count
19
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ReAlta Life Sciences
ReAlta Life Sciences offers a comprehensive portfolio of products and services, including RLS-0071 (pegtarazimod) and EPICC Platform.
Drug developed for rare inflammatory disease treatment purposes.
Platform used for dual-targeting inflammatory response moderation.
People of ReAlta Life Sciences
Unlock access to complete
Unlock access to complete
Funding Insights of ReAlta Life Sciences
ReAlta Life Sciences has successfully raised a total of $121.5M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $40 million completed in April 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ReAlta Life Sciences
ReAlta Life Sciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Marathon Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
New treatments for rare neurological and movement disorders are developed.
|
Locked | Locked | Locked |
Investor details for ReAlta Life Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ReAlta Life Sciences
Investment portfolio details for ReAlta Life Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ReAlta Life Sciences
Detailed financials for ReAlta Life Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Realta Life Sciences Comparisons
Peer comparison for ReAlta Life Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ReAlta Life Sciences
ReAlta Life Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
Detailed competitors of ReAlta Life Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Realta Life Sciences
Complete news archive for ReAlta Life Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ReAlta Life Sciences
ReAlta Life Sciences was founded in 2018 and raised its 1st funding round 2 years after it was founded.
ReAlta Life Sciences is headquartered in Norfolk, United States. It is registered at Norfolk, Virginia, United States.
Ulrich Thienel is the current CEO of ReAlta Life Sciences.
ReAlta Life Sciences is a funded company, having raised a total of $121.5M across 5 funding rounds to date.
As of Dec 31, 2021, the latest employee count at ReAlta Life Sciences is 19.
ReAlta Life Sciences, a clinical-stage company, is dedicated to addressing rare diseases through innovative drug development. The company has created a novel class of drugs utilizing the EPICC platform, which offers dual-targeting therapeutic capabilities to rebalance complement and inflammatory processes. Research and development initiatives are centered on acute inflammatory and rare diseases such as Hypoxic Ischemic Encephalopathy, Acute Exacerbations of COPD, Graft-versus-Host Disease, and Platelet Refractoriness. Solutions are developed to modify disease progression by moderating robust components of humoral and cellular inflammatory responses across various therapeutic areas.
ReAlta Life Sciences's top competitors include Moderna, Spark Therapeutics and BridgeBio.
ReAlta Life Sciences offers RLS-0071 (pegtarazimod) and EPICC Platform.
ReAlta Life Sciences has 1 investor. Key investors include Marathon Pharma.